药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Lumiracoxib
Acrivastine
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Vemurafenib.
Lumiracoxib
Niguldipine
The risk or severity of QTc prolongation can be increased when Niguldipine is combined with Vemurafenib.
Lumiracoxib
Lacidipine
The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Vemurafenib.
Lumiracoxib
Efonidipine
The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Vemurafenib.
Lumiracoxib
Aranidipine
The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Vemurafenib.
Lumiracoxib
Pinaverium
The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Vemurafenib.
Lumiracoxib
Trimebutine
The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Vemurafenib.
Lumiracoxib
Vilanterol
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Vemurafenib.
Lumiracoxib
Flumequine
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Vemurafenib.
Lumiracoxib
Indenolol
The risk or severity of QTc prolongation can be increased when Indenolol is combined with Vemurafenib.
Lumiracoxib
Chlorcyclizine
The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Vemurafenib.
Lumiracoxib
Eribulin
The risk or severity of QTc prolongation can be increased when Eribulin is combined with Vemurafenib.
Lumiracoxib
Bupranolol
The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Vemurafenib.
Lumiracoxib
Geranylgeranyl diphosphate
The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Vemurafenib.
Lumiracoxib
Farnesyl diphosphate
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Vemurafenib.
Lumiracoxib
Triptorelin
The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Vemurafenib.
Lumiracoxib
Pasireotide
The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Vemurafenib.
Lumiracoxib
Cariporide
The risk or severity of QTc prolongation can be increased when Cariporide is combined with Vemurafenib.
Lumiracoxib
Amisulpride
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Vemurafenib.
Lumiracoxib
Vernakalant
The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Vemurafenib.